[Proofs of efficacy].
Several factors are to be taken account in the assessment of the overall efficacy of a new antidepressant. There are rules governing the diagnostic categories, baseline scores and the conditions for the assessment of their course in the context of both placebo-controlled trials and studies versus reference products. As an illustration, two studies of clomipranine versus specific inhibitors of serotonin reuptake are reviewed. The author analyzes various studies conducted on venlafaxine, a new serotoninergic and noradrenergic product.
Boyer
P
P
Centre Hospitalier Sainte-Anne, Paris.
D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology / Q000627:therapeutic use; D002997:Clomipramine / Q000494:pharmacology* / Q000627:therapeutic use*; D003511:Cyclohexanols / Q000494:pharmacology / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005473:Fluoxetine / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009638:Norepinephrine / Q000037:antagonists & inhibitors; D017374:Paroxetine / Q000494:pharmacology / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000069470:Venlafaxine Hydrochloride
D000929:Antidepressive Agents, Tricyclic; D002997:Clomipramine; D003511:Cyclohexanols; D005473:Fluoxetine; D009638:Norepinephrine; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride
Les preuves de l'efficacité.